At the news
? BULLISHIMPACT 8/10 8-K filed Jun 8, 2026 at 06:11 ET
Nurix Therapeutics entered into a global license and collaboration agreement with Roche to co-develop and co-commercialize bexobrutideg, a potential best-in-class BTK degrader, across oncology, immunology, and neurology. Roche will make an upfront cash payment of $700 million, with total potential payments up to $2.3 billion including milestones, and development costs will be split 40/60 (Nurix/Roche) with a 50/50 U.S. profit share and tiered ex-U.S. royalties. This deal provides significant non-dilutive capital, validates the asset's potential, and accelerates Nurix's path to becoming a fully integrated biopharma, making this a transformative event for the company.
- Roche to pay $700 million upfront cash to Nurix for exclusive worldwide license to bexobrutideg (NX-5948), an oral BTK degrader.
- Total potential payments to Nurix of up to $2.3 billion including development, regulatory, and sales milestones.
- Nurix and Roche will co-develop and co-commercialize in the U.S. with a 50/50 profit/loss split; Roche leads ex-U.S. commercialization with tiered royalties (low-to-high teens).
- Global development costs shared 40% by Nurix and 60% by Roche.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access